Machine Learning Prediction of Progression to Dialysis in Patients With Polycystic Kidney Disease: Population-Based Retrospective Cohort Study
JMIR Medical Informatics · 2026-03-16 · 14 · e80343-e80343
DOI: 10.2196/80343 ↗At a glance
Kohortenstudie in JMIR Medical Informatics, published online on 2026-03-16. Written by Cheng-Hao Chang and 7 co-authors. Institution: Division of Nephrology, Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, No.95, Wen-Chang Road, Shih-lin District, Taipei, 111,…. Major MEDLINE topics: Disease Progression, Renal Dialysis, Machine Learning, Polycystic Kidney, Autosomal Dominant. 36 references. The full text is freely available in PubMed Central.
Abstract (original language)
Background
Autosomal dominant polycystic kidney disease (ADPKD), characterized by progressive cyst growth and renal decline, is the leading genetic cause of end‐stage renal disease.
Objective
This study aims to develop and validate machine learning (ML) models for predicting the risk of progression to dialysis in patients with ADPKD using a nationwide administrative database. Early identification of high-risk patients is critical for timely monitoring.
Methods
This retrospective cohort study used data from Taiwan’s National Health Insurance Research Database (2007‐2018) to identify newly diagnosed patients with ADPKD. Six ML algorithms, including logistic regression, random forest, and extreme gradient boosting (XGBoost), were employed to predict progression to dialysis. Models were developed using 10-fold cross-validation, with the Synthetic Minority Oversampling Technique applied within training folds to address class imbalance. An ensemble-based feature selection strategy was implemented to identify the most robust predictors and optimize final model performance. Model evaluation was conducted using a strict temporal split.
Results
The study included 1856 patients with ADPKD, of whom 302 (16.27%) progressed to dialysis. Multivariable Cox regression identified several significant risk factors, including age 66 years and older (hazard ratio [HR] 4.63, 95% CI 2.71‐7.92; P
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Division of Nephrology, Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, No.95, Wen-Chang Road, Shih-lin District, Taipei, 111, Taiwan, 886-912376017.
- Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, New Taipei City, Taiwan.
- AI Development Center, Fu Jen Catholic University, New Taipei City, Taiwan.
- Department of Medicine, Fu Jen Catholic University School of Medicine, New Taipei City, Taiwan.
- Department of Artificial Intelligence, Tamkang University, New Taipei City, Taiwan.
- Division of Nephrology, Department of Internal Medicine, Hsin-Jen Hospital, New Taipei City, Taiwan.
ORCID profiles: Cheng-Hao Chang, Mingchih Chen, Ming-Hsien Tsai, Yen-Chun Huang, Hung-Hsiang Liou, Ben-Chang Shia, Chingying Liang, Yu-Wei Fang
Cite
APA
Chang, C. H., Chen, M., Tsai, M. H., Huang, Y. C., Liou, H. H., Shia, B. C., Liang, C., & Fang, Y. W. (2026). Machine Learning Prediction of Progression to Dialysis in Patients With Polycystic Kidney Disease: Population-Based Retrospective Cohort Study. JMIR Medical Informatics, 14, e80343-e80343. https://doi.org/10.2196/80343
Vancouver
Chang CH, Chen M, Tsai MH, Huang YC, Liou HH, Shia BC, et al. Machine Learning Prediction of Progression to Dialysis in Patients With Polycystic Kidney Disease: Population-Based Retrospective Cohort Study. JMIR Medical Informatics. 2026;14:e80343-e80343. doi:10.2196/80343
BibTeX
@article{Chang2026,
author = {Chang, Cheng-Hao and Chen, Mingchih and Tsai, Ming-Hsien and Huang, Yen-Chun and Liou, Hung-Hsiang and Shia, Ben-Chang and Liang, Chingying and Fang, Yu-Wei},
title = {Machine Learning Prediction of Progression to Dialysis in Patients With Polycystic Kidney Disease: Population-Based Retrospective Cohort Study},
journal = {JMIR Medical Informatics},
year = {2026},
volume = {14},
pages = {e80343--e80343},
doi = {10.2196/80343}
}
EUVIMED